论文部分内容阅读
目的 :探讨黄芪注射液对急性心肌梗死 (AMI)静脉溶栓治疗后再通及并发症的影响。方法 :82例AMI患者随机分为黄芪组 (38例 )和对照组 (44例 )。2组均以尿激酶 (10 0～ 15 0 )× 10 4U常规溶栓治疗 ,黄芪组在溶栓治疗的同时静滴黄芪注射液 6 0 ml加入 5 %葡萄糖 (或生理盐水 ) 2 5 0 ml,每日 1次 ,连用 10日后比较 2组再通标准各项指标及并发症情况。结果 :2组再通标准指标中 ,再灌注性心律失常发生率黄芪组为 5 5 .5 6 % ,明显低于对照组 82 .86 % ,2组有显著性差异 (P<0 .0 5 ) ;心力衰竭及梗死后心绞痛发生率 (7.89%和 2 .6 3% )均明显低于对照组 (31.82 %和 2 0 .45 % ) ,P均 <0 .0 5 ;休克及总病死率也均低于对照组。结论 :黄芪注射液配合尿激酶溶栓治疗 AMI,可提高疗效 ,减少再灌注性心律失常等并发症和降低病死率。
Objective: To investigate the effect of Astragalus injection on recanalization and complications after intravenous thrombolysis in patients with acute myocardial infarction (AMI). Methods: 82 AMI patients were randomly divided into Astragalus group (38 cases) and control group (44 cases). Both groups were given urokinase (10 0 ~ 150) × 10 4U conventional thrombolytic therapy, astragalus group thrombolytic therapy while Astragalus injection 60 ml added 5% glucose (or normal saline) 250 ml , Once a day, once every 10 days after comparing the two groups and then through the standard indicators and complications. Results: The incidence of reperfusion arrhythmia in the two recanalization criteria was 55.65% in astragalus group, which was significantly lower than 82.86% in control group (P <0.05) ); The incidence of heart failure and post-infarction angina (7.89% and 2.63%) were significantly lower than that of the control group (31.82% and 20.45%), P <0.05; shock and overall mortality Also lower than the control group. Conclusion: Astragalus injection combined with urokinase thrombolytic therapy for AMI can improve curative effect, reduce complications such as reperfusion arrhythmia and reduce mortality.